CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD

Robert Zeiser

Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6

Rush University Medical Center

E. Bhaimia

Steroid-Refractory GvHD Management: When to Switch From Steroids

Giuseppe Francesco Milone

CAR NK Cells: Next Generation Cell Therapies for Cancer

University of Colorado Cancer Center

K. Rezvani

Unmet Needs in GvHD and the Role of Axatilimab

Jose Perez Simon

Approaches to Preventing and Treating GVHD in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

N. Hossain

Axatilimab in Chronic GVHD: Updates From the AGAVE-201 Study

Zachariah DeFilipp

Updates in Transplantation and GVHD From Recent Meetings

UChicago Medicine

M. Nawas

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Chronic GVHD: Results from Agave-201 - Axatilimab at 3 Different Dos…

Insights from 2023 ASH Annual Meeting

D. Wolff

Clonal Hematopoiesis Is Common in Unrelated Stem Cell Donors but Has…

Insights from 2023 ASH Annual Meeting

J. Schetelig